HALOZYME THERAPEUTICS, INC. (HALO) — Institutional Holders, Q2 2026 (page 8)

715 institutional investment managers reported a HALO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $10.5B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 701 to 715. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

HALO 13F holders ranked 701–715 of 715

Institutional investors reporting a position in HALOZYME THERAPEUTICS, INC. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Hughes Financial Services#701 · 5 sh$391.00+66.7%
Godfrey Financial Associates#702 · 5 sh$391.00-28.6%
MV CAPITAL MANAGEMENT#703 · 4 sh$314.00+100.0%
GHP Investment Advisors#704 · 3 sh$235.000.0%
Activest Wealth Management#705 · 3 sh$235.00New
Quarry#706 · 3 sh$235.00New
Planning Strategies#707 · 3 sh$235.00—
DecisionPoint Financial#708 · 3 sh$232.00New
RAFFA WEALTH MANAGEMENT#709 · 2 sh$157.00+100.0%
3 FACTOR INDEXING#710 · 2 sh$157.000.0%
MARYLAND CAPITAL ADVISORS#711 · 1 sh$79.00—
American Capital Advisory#712 · 1 sh$79.000.0%
Plante Moran Financial Advisors#713 · 1 sh$78.00New
Navigoe#714 · 8 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#715 · 136,298 sh—0.0%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.